Cancer Therapy AdvisorNeoadjuvant Nivolumab Plus Chemo Deemed New Standard Care for Resectable Non-Small Cell Lung Cancer (NSCLC)

In this trial of nivolumab + chemotherapy vs. chemotherapy alone, nivolumab prolonged EFS by nearly 11 months and improved the pathologic complete response rate more than tenfold. There was also a trend toward improved OS with nivolumab. The study also reported an EFS improvement with nivolumab in both squamous and non-squamous NSCLC. Grade 3-4 treatment-related adverse events occurred in 34% of patients in the nivolumab arm and 37% of those in the chemotherapy-alone arm.